Author

Lin Zhu

University of Science and Technology of ChinaORCID 0000-0001-5772-9482Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Lin Zhu1 paper

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Organism:human· 2 Assay:scRNA-seq· 2 Approach:statistical model· 2 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Chuang GuoiD· 2 shared Jun LiniD· 2 shared Kun QuiD· 2 shared Pengfei CaiiD· 2 shared Biao ZhangiD· 1 shared Bin LiiD· 1 shared Bin SuiD· 1 shared Bin ZouiD· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenomics

Chuang GuoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Large-scale single-cell analysis reveals critical immune characteristics of COVID-19 patients

Xianwen Ren, Wen Wen, Xiaoying Fan, Wenhong Hou, Bin Su, Pengfei Cai, Jiesheng Li, Yang Liu, Fei Tang, Fan Zhang, Yu Yang, Jiangping He, Wenji Ma, Jingjing He, Pingping Wang, , Zemin Zhang

This study uses single-cell RNA sequencing to analyze immune responses in COVID-19 patients, identifying key immune cell changes and molecular pathways linked to disease severity.

bioRxiv · Oct 29, 2020 · PreprintGenomics

Single-cell analysis of severe COVID-19 patients reveals a monocyte-driven inflammatory storm attenuated by Tocilizumab

Chuang Guo, Bin Li, Huan Ma, Xiaofang Wang, Pengfei Cai, Qiaoni Yu, Lin Zhu, Liying Jin, Chen Jiang, Jingwen Fang, Qian Liu, Dandan Zong, Wen Zhang, Yichen Lu, Kun Li, , Kun Qu

The paper uses single-cell analysis to show that Tocilizumab reduces monocyte-driven inflammation in severe COVID-19 but does not fully suppress immune responses.

Nature Communications · Aug 6, 2020Peer-reviewedGenomics